OCTIMET Oncology NV awarded €1.12 million grant from VLAIO
OCTIMET oncology NV, based at the JLINX facility in Beerse, Belgium, with a focus on the development of selective MET kinase inhibitory drug candidates, today announced it has received a €1.12 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, former IWT.
OCTIMET Oncology NV, a translational accelerator, focusing on creating value for patients and investors by providing rapid clinical proof of concept for cancer therapies, through innovative clinical development strategies and patient centered biomarker approaches, announces that it has been awarded a €1.12 million industrial R&D Project Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used by OCTIMET to generate further preclinical in vitro and in vivo data on innovative combination options with the lead compound OMO-1 and both novel and approved therapies. Work will be carried out in collaboration with expert CRO’s and academic partners including the VIB.
Timothy Perera, CEO of OCTIMET Oncology NV says: "We are delighted with the continued financial support we have received from VLAIO. This grant gives us the opportunity to expand our ability to generate preclinical data to guide the selection of the most suitable combination options in the clinic”.
Other news from the department business & finance
